Needham & Company LLC reiterated their buy rating on shares of Verrica Pharmaceuticals (NASDAQ:VRCA – Free Report) in a report released on Thursday morning, Benzinga reports. They currently have a $10.00 price objective on the stock. A number of other research firms also recently commented on VRCA. Royal Bank of Canada raised their target price […]
Verrica Pharmaceuticals (NASDAQ:VRCA – Free Report) had its price objective lifted by Royal Bank of Canada from $11.00 to $14.00 in a research report released on Tuesday morning, Marketbeat reports. The brokerage currently has an outperform rating on the stock. Separately, Needham & Company LLC upgraded shares of Verrica Pharmaceuticals from a hold rating to […]